Sign in
Not yet recruitingPhase 4

Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission

Key facts

Who runs it
Istituto Giannina Gaslini
Where
Belgium, Czechia, Denmark, Italy, Lithuania, Portugal, and Spain24 sites in 7 countriesChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 4
People taking part
166 people, planned
Started
1 Jan 2025
Expected to end
1 Jan 2029
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Treatment medication withdrawal strategy
Record updated
1 October 2024

Who can take part

Age
2 years to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • - Children with a diagnosis of JIA according to the ILAR classification criteria
  • JIA patients who satisfy criteria for inactive disease for a minimum of 6 continuous months while still taking medication
  • Patients who have been treated with cs/b/bs/ts DMARDs according to the label indication
  • Ability to comply with the entire study procedures, ability to communicate meaningfully with the investigational staff, competence to give written informed consent; to be applied to the parents and/or patients, as appropriate
  • Duly executed, written, informed consent obtained from the patient's parents/legal guardian
  • Female of child-bearing potential must have a negative pregnancy test at the beginning of the trial. If sexually active, they must have no intention of conceiving while on treatment with antirheumatic drugs

Who cannot take part

  • Patients who received glucocorticoid treatment 3 months prior to baseline visit
  • Patients who had previously unsuccessfully attempted tapering cs/b/bs/tsDMARDs
  • Prior or current history of other significant concomitant illness(es) that, according to the Investigator's judgment, would adversely affect the patient's participation in the study
  • Patients with severe disease-related ocular damage and who need systemic treatment for uveitis
  • Any other medical condition or laboratory examination which in the opinion of the caring physician should exclude the patient from participation to the study
  • - Patients with systemic JIA according to ILAR criteria
  • Patients with undifferentiated arthritis according to ILAR criteria
  • Patients with severe damage as per caring physician measured

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 18 years old?

This trial has no sites in United States.

It has sites in 7 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Biologic therapies made clinical remission an achievable goal for most juvenile idiopathic arthritis (JIA) patients. Nevertheless, antirheumatic drugs have side effects and are costly. Currently, no guidelines exist for withdrawing drugs in JIA patients with clinical inactive disease (CID). Relapses following the withdrawal of antirheumatic drugs are common. To establish an optimal timeline for treatment discontinuation is a major unmet need in pediatric rheumatology.

Read full original descriptionShow less

It is hypothesized that biomarkers-guided early withdrawal of antirheumatic drugs in patients achieving clinical, imaging and biological remission is safe and more effective compared to the standard practice of maintenance of stable treatment over 12 months.

The 2 groups in the trial

  • Biomarker-guided drug withdrawalTreatment being tested

    Patients with inactive disease, absence of sublinical synovitis at the joint level and normal S100A8/9 and hs-CRP leves will be randomly assigned to either an early biomarker-guided drug withdrawal protocol (interventional arm) or continuation of ongoing therapy at unchanged dose for an additional 6 months and then gradual tapering (control arm). Patients will be evaluated at baseline, then every 3 months if still on treatment and every 6 months after drug withdrawal. At each timepoint the following procedures will be performed: joint assessment, Physician's Global Assessment of Overall Disease Activity, JAMAR, Uveitis assessment (in ANA positive patients), Hematology, chemistry, CRP, ESR, urine analysis according to drug specific schedule and Good Clinical Practice (GCP). Drug Adverse Events will be collected (MedDRA). MSUS and serum biomarkers quantification (S100A8/9, hs-CRP) will be repeated every 3 months until month 18 in patients with subclinical synovitis and pathologic values

    Treatment: Treatment medication withdrawal strategy

  • Gradual taperingNo study treatment, for comparison

    The control arm will continue ongoing therapy at unchanged dose for an additional 6 months and then will gradually taper the therapy.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission: a Randomized Clinical Trial Comparing Early Versus Late Drug Withdrawal Combining Imaging and Multi-Omics
Fit questions
Built from NCT06618937, who can take part
Record updated
1 October 2024